financetom
Business
financetom
/
Business
/
Box Shares Climb After Q2 Results: EPS Beat, Revenues Beat, Guidance Above Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Box Shares Climb After Q2 Results: EPS Beat, Revenues Beat, Guidance Above Estimates
Aug 29, 2024 8:19 AM

Box, Inc. ( BOX ) reported its second-quarter financial results after Tuesday's closing bell. Here's a look at the details from the report. 

The Details: Box reported quarterly earnings of 44 cents per share, which beat the analyst consensus estimate of 40 cents by 10%. Quarterly revenue came in at $270.039 million, which beat the consensus estimate and is a 3.29% increase year-over-year.

Remaining performance obligations (RPO) as of July 31, 2024, were $1.272 billion, a 12% increase from the prior year’s quarter. Billings for the second quarter were $256.4 million, a 10% increase from the second quarter of last year, and operating margin was a record 28.4% of revenue.

“As we enter the era of Intelligent Content Management, Box is delivering a singular platform that can power the lifecycle of content with intelligence built right in,” said Aaron Levie, co-founder and CEO of Box.

“With Box AI and strategic technology acquisitions like Alphamoon, the Box Intelligent Content Cloud can now support more use-cases across the enterprise than traditional ECM, dramatically expanding our market opportunity,” Levie added.

Read Next: Apple Announces CFO Transition, iPhone 16 Debut: What To Know

Outlook: Box sees third-quarter earnings between 41 cents and 42 cents per share, versus the 40-cent estimate, and revenue in a range of $274 million to $276 million, versus the $269.182 million estimate.

The company expects fiscal year 2025 earnings of between $1.64 and $1.66 per share, versus the $1.57 estimate, and fiscal year revenue in a range of $1.086 billion to $1.09 billion, versus the $1.079 billion estimate.

BOX Price Action: According to Benzinga Pro, Box shares are up 4.61% after-hours at $30.15 at the time of publication Tuesday.

Read Also:

What’s Going On With EV-Maker Rivian’s Stock?

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Knight Therapeutics Anti-Cancer Treatment Gains Approval in Mexico
Knight Therapeutics Anti-Cancer Treatment Gains Approval in Mexico
Oct 17, 2024
08:57 AM EDT, 10/15/2024 (MT Newswires) -- Knight Therapeutics ( KHTRF ) on Tuesday said its Mexican affiliate has obtained regulatory approval for Minjuvi (tafasitamab) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that aren't eligible for autologous stem cell transplantation. The treatment is expected to launch in the first half of next...
Platinum Equity's Ingram Micro seeks up to $5.4 bln valuation in US IPO
Platinum Equity's Ingram Micro seeks up to $5.4 bln valuation in US IPO
Oct 17, 2024
* Ingram, PE firm seek to raise as much as $428 mln * Platinum Equity will remain controlling shareholder post-IPO * Ingram set to go public again, 28 years after initial NYSE debut (Adds background on company and IPO details in paragraphs 4-12) Oct 15 (Reuters) - Ingram Micro is targeting a valuation of up to $5.42 billion in its...
S&P Global Names Eric Aboaf CFO
S&P Global Names Eric Aboaf CFO
Oct 17, 2024
08:57 AM EDT, 10/15/2024 (MT Newswires) -- S&P Global ( SPGI ) said Tuesday that it has named Eric Aboaf as its chief financial officer, effective February. Aboaf was most recently the CFO of State Street (STT). Price: 528.96, Change: +1.44, Percent Change: +0.27 ...
Johnson & Johnson Reports Positive Phase 2/3 Study Results for Nipocalimab in Myasthenia Gravis Adolescents
Johnson & Johnson Reports Positive Phase 2/3 Study Results for Nipocalimab in Myasthenia Gravis Adolescents
Oct 17, 2024
08:59 AM EDT, 10/15/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday its phase 2/3 Vibrance-MG study of nipocalimab in adolescents with generalized myasthenia gravis met its primary endpoint by achieving sustained disease control. Treatment with nipocalimab plus standard of care reduced immunoglobulin G levels by 69% over 24 weeks, the company said. The combination treatment also...
Copyright 2023-2025 - www.financetom.com All Rights Reserved